The FY2025 (Jun) proxy of Anaptysbio names 15 peer companies for pay. Among Anaptysbio and these peers, CEO pay was 2nd highest of 3 and total shareholder return was the highest of 3.
2nd highest of 3in Anaptysbio and its pay peers, FY2025 (Jun) by CEO pay:
$4.7M$8.5M
1st highest of 3in Anaptysbio and its pay peers, FY2025 (Jun) by total shareholder return:
$84$156
Pay peer group, FY2025 (Jun) proxy
| Kymera Therapeutics | ||
| Kura Oncology | ||
| ALX Oncology | Not disclosed | Not disclosed |
| Allogene Therapeutics | Not disclosed | Not disclosed |
| Apogee Therapeutics | Not disclosed | Not disclosed |
| Arcellx | Not disclosed | Not disclosed |
| Astria Therapeutics | Not disclosed | Not disclosed |
| Centessa Pharmaceuticals | Not disclosed | Not disclosed |
| IGM Biosciences | Not disclosed | Not disclosed |
| Janux Therapeutics | Not disclosed | Not disclosed |
| Jasper Therapeutics | Not disclosed | Not disclosed |
| Pilant Therapeutics | Not disclosed | Not disclosed |
| Replimune Group | Not disclosed | Not disclosed |
| Xencor | Not disclosed | Not disclosed |
| iTeos Therapeutics | Not disclosed | Not disclosed |
15 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.